Skip to content

A prospective double-blind randomised controlled trial of the effect of a prebiotic mixture of bifidogenic oligosaccharides on enteral tolerance in preterm infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72367147
Enrollment
4
Registered
2006-09-29
Start date
2005-12-02
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neonatal Diseases Neonatal Diseases

Interventions

Suitable babies less that 32+6 weeks gestation who are also of appropriate birth weight for gestational age will be identified by neonatal unit staff. Parent will be approached and explanation of stud

Sponsors

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Written informed parental consent 2. Preterm infants, appropriately grown for gestational age (Child Growth Foundation UK reference), with a gestational age of 32 weeks, whose mother agree to the use of formula if they are unable to or do not wish to breastfeed or are not able to provide sufficient breast milk

Exclusion criteria

Exclusion criteria: 1. More than 72 hours exclusive parenteral nutrition 2. Immediately life-threatening congenital abnormality 3. Any condition requiring major surgery

Design outcomes

Primary

MeasureTime frame
1. Number of days from birth to establish a total (sole formula or formula with breast milk) daily enteral intake of 150 ml/kg 2. Number of days between birth and 28 days that a total (sole formula or formula with breast milk) daily enteral intake of at least 150 ml/kg is tolerated

Secondary

MeasureTime frame
1. Gain in weight, length and head circumference (change in Z score between birth and 40 weeks postmenstrual age) 2. Faecal flora (colony forming units/g stool of Bifidus sp., Lactobacilli sp., and pathogenic micro-organisms) 3. Faecal calprotectin 4. Stool characteristics 5. Gastrointestinal tolerance 6. Fluid balance (the number of days between trial entry and 28 days where serum sodium exceeds 148 mmol/l or serum creatinine exceeds 150 micromol/l) 7. Proven necrotising enterocolitis according to predefined diagnostic criteria 8. Proven bloodstream infection according to predefined diagnostic criteria

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026